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 1 
INTRODUCTION 
Since the discovery of atrial natriuretic peptide (ANP) and B-type natriuretic 
peptide (BNP) over two decades ago, the endocrine role of the heart in the control 
of salt and water balance and cardiac structure has been clearly established (1-3). 
Both ANP and BNP are secreted by the heart and are endogenous ligands for the 
particulate guanylyl cyclase-A receptor, mediating their biological actions via the 
second messenger 3’,5’ cyclic guanosine monophosphate (cGMP) and consequent 
activation of cGMP-dependent protein kinase, phosphodiesterases and ion 
channels. Their actions include vasodilation, natriuresis, suppression of the renin-
angiotensin-aldosterone system and inhibition of both cardiomyocyte hypertrophy 
and cardiac fibroblast activation (4).  
The natriuretic peptide precursor A gene (NPPA) lies in tandem with the 
BNP gene on chromosome 1 and encodes for the prohormone from which ANP and 
N-terminal-proANP (NT-proANP) are derived in equimolar amounts (5). Most 
recently, Newton-Cheh and co-workers reported in a seminal study that two 
common genetic variants in the 3’ untranslated region and 2 kb downstream of 
NPPA, the single nucleotide polymorphisms (SNPs) rs5068 and rs198358, 
respectively, are associated with increased circulating levels of NT-proANP, N-
terminal-proBNP (NT-proBNP), lower blood pressure (BP), and reduced 
prevalence of hypertension (6).  This recent study underscores the importance of 
ANP and BNP in BP homeostasis as well as the impact of common genetic 
variations on cardiovascular function as predicted from the early studies in mouse 
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models in which ANP gene disruption resulted in increased BP (4,7).  
Increasing evidence supports the view that both ANP and BNP may also play 
a fundamental role in metabolic regulation. Indeed, low levels of ANP infusion in 
healthy volunteers increase free fatty acids mobilization and lipid oxidation (8).  In 
humans with heart failure, ANP infusion results in increased circulating levels of 
the adipokine adiponectin (9), which is an important regulator of glucose and lipid 
metabolism and possesses anti-hypertrophic properties in cardiomyocytes (10-12). 
In mice, activation of the guanylyl cyclase-A receptor has been shown to slow 
gastric emptying (13). Most recently, Miyashita et al. demonstrated in a mouse 
model that BNP overexpression prevented the development of obesity in response 
to a high fat diet (14). Moreover, in humans rs198389, a SNP in the promoter 
region of the BNP gene which increases circulating BNP, is associated with 
reduced risk for type 2 diabetes mellitus (15,16).  
 The impact of rs5068 on the metabolic phenotype in the general population is 
unknown.  In the current study we hypothesized that rs5068, which has previously 
been associated with higher levels of ANP and BNP and lower BP, is also 
associated with a protective cardiometabolic phenotype in the general population. 
To test this hypothesis, we used a subset of a large, well-characterized sample of 
the general population 45 years and older from Olmsted County, Minnesota both to 
reconfirm the elegant studies of Newton-Cheh and co-workers on BP and to extend 
our studies to define the cardiometabolic phenotype of rs5068 in the general 
community (17).  
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METHODS 
This study was approved by the Mayo Clinic Institutional Review Board.   
Study population 
We analyzed a subset of clinically well-characterized population-based 
sample of the general population 45 years or older living in Olmsted County, 
Minnesota in 1997-2000. This population was first characterized as part of the 
National Institutes of Health-funded Prevalence of Left Ventricular Dysfunction 
Study and Cardiac Peptides in Cardiorenal Regulation (RO1 HL55502 and 
HL36634). The design and selection criteria of the above study as well as the 
characteristics of the Olmsted County population have been previously described 
(17,18). This population was characterized clinically, biochemically, and by 
echocardiography. From the 2027 subjects in this study from whom there were 
collected DNA samples a total of 1608 subjects were successfully genotyped and 
were included in this study. 
Body mass index (BMI) was measured as kilograms per (meter)
2
. Obesity 
was defined as BMI 30 kg/m2. Waist circumference was measured in centimeters 
at the top of the umbilicus. In accordance with the National Cholesterol Education 
Program Adult Treatment Panel III criteria, metabolic syndrome was defined by the 
presence of 3 or more of the following criteria: (1) central obesity defined as a 
waist circumference greater than 102 cm in men and greater than 88 cm in women, 
(2) triglyceride level higher than 150 mg/dL (to convert to mmol/L, multiply by 
0.0113), (3) high-density lipoprotein cholesterol level less than 40 mg/dL (to 
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convert to mmol/L, multiply by 0.0259) in men and less than 50 mg/dL in women, 
(4) blood pressure of 130/85 mm Hg or higher, and (5) fasting glucose level of 110 
mg/dL (to convert to mmol/L, multiply by 0.0555) or higher. Hypertension was 
diagnosed using Joint National Committee VI criteria (19).  
Genotyping  
Genotyping of rs5068 was carried out on 1608 subjects using TaqMan 
(Applied Biosystems, Foster City, CA) according to the manufacturer’s 
instructions, using 10-20ng DNA.  Primers and probes were Assay-by Design 
(Applied Biosystems).  Following PCR amplification, end reactions were read on 
the ABI Prism 7900ht using Sequence Detection Software (Applied Biosystems).  
The quality value percentage is a quality metric that indicates the reliability of 
called genotypes generated by the SDS software.  The quality value was calculated 
by using ABI’s proprietary calling algorithm determining how well that sample fits 
into the cluster.  Genotypes less than 95% are located further from their clusters 
and have a lower reliability.  An electronic data file was generated that contains 
genotypes and the quality value. 
Natriuretic peptide assays 
Plasma NT-proANP levels were available in a subgroup of 1485 subjects 
using a radioimmunoassay (Phoenix Pharmaceuticals, Belmont, CA) (20). NT-
proBNP values were measured in a subgroup of 1566 subjects using an 
electrochemiluminescence immunoassay (Roche Diagnostics, Indianapolis, 
Indiana) (21).  
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Doppler echocardiography 
All echocardiograms were performed with the same echocardiographic 
instrument (HP-2500, Palo Alto, California) and were interpreted by a single 
echocardiologist blinded to clinical data.  Two-dimensional and color Doppler 
imaging were performed to screen for valvular stenosis and regurgitation.  In each 
subject, ejection fraction was measured and diastolic function was classified as 
mild, moderate, and severe as previously described (17). Left ventricular (LV) 
dimension and mass and left atrial volume were calculated from M-mode and 2-D 
measurements, respectively, and were indexed to body surface area (22-24). LV 
mass was calculated according to the Devereux formula. Presence of LV 
hypertrophy was defined on the basis of LV mass index greater than 130 g/m
2 
for 
men and greater than 100 g/m
2
 for women (25). Presence of left atrial enlargement 
was defined as left atrial volume index >33 ml/m
2 
in men and >30 ml/m
2 
in females 
(26).  
Statistical Analysis  
Data pertaining to patient demographics and clinical characteristics were 
summarized with descriptive statistics. These included counts and percentages for 
categorical and ordinal variables, or medians and interquartile ranges for 
continuous variables. To test for an association with the rs5068 genotype, 
specifically whether or not a subject had at least one copy of the minor G allele, 
each clinical factor was modeled as the dependent variable via linear regression (or 
logistic regression if the factor was binary) with rs5068 genotype as the explanatory 
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variable. All modeling was performed unadjusted and adjusted for potential 
confounding variables such as age and gender. Further adjustments were done for 
BMI and NT-proANP.  Due to highly skewed distributions of the NT-proANP and 
NT-proBNP biomarkers, a probit transformation was applied to the ranked values 
of each, thus producing normal distributional properties. Similarly, other skewed 
variables including C-reactive protein, serum glucose, insulin and triglycerides 
levels were transformed to approximate normality, typically using the logarithmic 
transform.  Furthermore, since age and gender are highly correlated with these 
biomarkers and with several other clinical factors, both were treated as adjusting 
covariates in the logistic models to control for their potential confounding. 
Although multiple hypothesis tests were carried out, a nominal 2-sided significance 
level of 0.05 was used with no formal adjustment for multiple testing. Given that 
about 30 to 40 variables were evaluated, the expected number of about 1 or 2 
nominally significant results by chance alone should be considered in the 
interpretation of our findings. All analyses were carried out using the SAS 
statistical software package (Version 8.2, SAS Institute Inc., Cary, NC). 
 
RESULTS   
Prevalence of rs5068 and Circulating Natriuretic Peptides  
 From collected DNA samples on 2027 subjects, a total of 1608 subjects were 
successfully genotyped and included in this study. Genotype frequencies of rs5068 
were AA: 89.9% (n=1445), AG: 9.7% (n=157), and GG: 0.4% (n= 6), 
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corresponding to a minor allele frequency of 5.3%. The distribution was in Hardy-
Weinberg equilibrium (p=0.435). Due to the low frequency of homozygotes for the 
G allele, all analyses were performed assuming a dominant model with AG and GG 
genotypes combined. The characteristics of the study population are summarized in 
Table 1. Neither age nor gender were significantly associated with the genotype, 
though there was a trend toward a higher prevalence of females among those who 
had at least one minor allele compared to those with none (58% vs 52%; age-
adjusted p=0.122). Importantly, the presence of at least one copy of the minor allele 
was associated with increased plasma levels of NT-proANP (median 2584 vs 2188 
pg/mL), both unadjusted (p<0.001), and after adjustment for age, gender and BMI 
(p=0.006). In contrast, circulating levels of NT-proBNP were not significantly 
different between genotypes. 
Cardiovascular Phenotype  
Controlling for age and gender, the G allele was significantly associated with 
lower systolic BP (delta = -4.28 mmHg, p=0.011) but not with diastolic BP (delta = 
-1.24 mmHg, p=0.132) (Table 1). The effect on SBP remained marginally 
significant after adjusting for BMI (p=0.051) or further adjusting for NT-proANP 
(p=0.054). The analysis of left atrial volume, LV structure and function as 
determined by echocardiography (LV ejection fraction, LV dimensions, LV mass, 
and LV volume index) did not reveal any significant associations with the rs5068 
genotype.   
With regard to cardiovascular diseases, in a model adjusted for age and 
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gender the regression analysis showed that fewer minor allele carriers of rs5068 
had a history of myocardial infarction (adjusted odd ratio= 0.29,  p=0.042) whereas 
in a model adjusted also for BMI the result was slightly attenuated (odd ratio= 0.32, 
p=0.061) (Table 2). There was no significant association between genotype and 
hypertension, coronary artery disease, congestive heart failure, atrial fibrillation, or 
cerebrovascular accident. 
Metabolic Phenotype  
In a regression model adjusted for age and gender the presence of at least one 
copy of the G allele was associated with lower BMI (delta= -1.22 kg/m
2
, p=0.006; 
Table 3) and waist circumference (delta= -2.45 cm, p=0.021), as well as reduced 
rate of obesity (odds ratio=0.54, p=0.002; Figure 1A). In addition, the minor allele 
was associated with higher levels of HDL cholesterol (delta= 2.46 mg/dL, 
p=0.019), lower plasma values of C-reactive protein (ratio=0.82, p=0.027; Table 3) 
and, although not significant, with lower levels of insulin in subjects free of 
diabetes mellitus type 1 and 2 (ratio=0.91, p=0.069; Table 3). Moreover, having at 
least one minor allele was associated with lower prevalence of metabolic syndrome 
(odds ratio= 0.58, p=0.025; Figure 1B). After including BMI in the regression 
model the association between the rs5068 minor allele HDL cholesterol, C – 
reactive protein values and metabolic syndrome failed to remain significant (Table 
3). However, the association of the G allele with BMI, obesity and waist 
circumference remained significant after adjusting for NT-proANP. Genotypes did 
not differ regarding plasma concentration of total and low-density lipoprotein 
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cholesterol, triglycerides, and fasting glucose (Table 3).  Of note, the proportion of 
subjects with antilipemic treatment was similar between the two genotype groups 
(17% in both), as was the prevalence of diabetes mellitus type 2 (Table 2).  
 
DISCUSSION 
 While ANP and BNP have been known to play a fundamental role in 
cardiorenal homeostasis, significant metabolic actions of natriuretic peptides have 
only recently emerged. Here we report for the first time that an ANP genetic variant 
associated with higher NT-proANP levels is associated with a favorable metabolic 
profile, primarily via its association with BMI, and that it is also associated with a 
favorable cardiovascular profile. Specifically, according to a regression analysis 
adjusted for age and gender the minor allele of rs5068, a SNP of the NPPA gene 
previously associated with increased NT-proANP levels and lower risk of 
hypertension, correlates not only with reduced systolic BP and lower prevalence of 
myocardial infarction but also with lower BMI, prevalence of obesity, waist 
circumference, higher levels of HDL cholesterol as well as lower values of C-
reactive protein. Carriers of the minor allele are also characterized by a lower risk 
of metabolic syndrome.  
In our study of residents in Olmsted County, Minnesota, the genotype 
frequencies for rs5068 were similar to the recently reported Framingham Heart 
Study and Malmö Diet and Finrisk97 cohorts (6).  Similar to this recent report, we 
observed that the G allele was associated with increased levels of NT-proANP. 
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This increase in NT-proANP is notable, as Itoh et al reported that it is produced in 
equimolar amounts with ANP and represent a robust estimator of ANP secretion 
from the heart (27,28). 
While a major stimulus for ANP release is increased atrial stretch, there is no 
indication that this would explain the higher levels associated with the minor allele 
in our study as there were no differences in terms of congestive heart failure, atrial 
fibrillation or left atrial enlargement across genotypes, and moreover, BP levels 
were lower in the group characterized by the presence of the minor allele. Newton-
Cheh et al. speculated that rs5068, which is located in the 3’ untranslated region, 
could affect transcript stability and result in higher ANP production. These 
investigators pointed out that this mechanism would not explain the higher BNP 
levels seen in their study, the levels of which would be expected to decrease in a 
compensatory manner if the primary mechanism was an increase in ANP 
production. They propose an alternative explanation that rs5068 resides in a shared 
enhancer element that coordinately regulates expression of the adjacent NPPA and 
NPPB genes. However, unlike in the study by Newton-Cheh et al., levels of NT-
proBNP were not different between genotypes in our cohort. This discrepancy 
could be a consequence of the smaller size of the sample analyzed in our study as 
well as the different assay performed.  
Given the known metabolic effects of natriuretic peptides and the increased 
levels of NT-proANP and NT-proBNP associated with the rs5068 minor allele, it 
was our main objective to define the metabolic phenotype associated with the 
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rs5068 genotype. Indeed, minor allele carriers not only showed a favorable 
cardiovascular profile characterized by lower systolic BP and lower prevalence of 
myocardial infarction, but they also had a favorable metabolic phenotype 
characterized by lower BMI, waist circumference, and prevalence of obesity. 
Furthermore, they had higher levels of HDL cholesterol and lower levels of C-
reactive protein.  The differences in HDL and C-reactive protein cannot be 
explained by anti-lipemic treatment, as both genotypes were similar in this regard. 
Consistent with all these findings, the prevalence of the metabolic syndrome in our 
study population was lower in the minor allele carriers.  
These associations support once more the view of a significant, clinically 
relevant metabolic action of natriuretic peptides more specifically ANP. 
Interestingly, Miyashita et al. provided recent important findings regarding the 
critical role of natriuretic peptides and guanylyl cyclase-A receptor stimulation in 
lipid catabolism and glucose intolerance. Transgenic mice overexpressing BNP 
were protected against obesity and insulin resistance induced by high fat-diet while 
transgenic mice overexpressing cGMP-dependent protein kinase revealed a 
significant reduction in body weight and higher insulin sensitivity compared to wild 
type mice, even on standard diet. Both models showed augmented muscle 
mitochondrial biogenesis and fat oxidation (14). Of note, acute infusion of ANP in 
humans has been reported to promote insulin secretion and inhibit glucagon 
secretion (29),(30). However, in our study this direct insulin-increasing effect of 
ANP is likely to be offset by the favorable metabolic status of rs5068 minor allele 
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carriers, who would be expected to have improved insulin sensitivity and thus 
generally lower insulin levels.   
While our study is an association study which cannot establish a causal 
relationship between increased NT-proANP and cardiovascular-metabolic 
phenotype, our findings support the emerging metabolic role of guanylyl cyclase-A 
activation. The capacity of ANP and BNP to promote lipid mobilization and 
oxidation, slow gastric emptying, decrease blood pressure and body weight, and 
increase insulin sensitivity provide strong arguments in favor of the natriuretic 
peptide/guanylyl cyclase-A/cGMP signaling system’s capacity to enhance 
metabolic function and phenotype (6,8,13,14).  
Thus, our findings with respect to the rs5068 genetic variant of the ANP 
gene in a subset of a population-based sample of the adult general population from 
Olmsted County, Minnesota support the hypothesis of a heritable basis for a 
favorable cardiometabolic profile. Specifically, the presence of at least one copy of 
the minor allele of rs5068 was associated with a higher circulating level of NT-
proANP, and may identify individuals with lower risk for cardiovascular and 
metabolic diseases.  
Despite no formal adjustment for multiple comparisons, the consistency of 
the main significant findings with previous results, as well as the number of 
significant findings, tend to support the association between the minor allele of 
rs5068 and a favorable cardiometabolic phenotype. We acknowledge that a 
potential criticism of the study is that significant associations with multiple 
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comparisons occurred by chance.  Based on the null distribution of p-values from 
the approximately 40 unique associations tested, the expected number of type I 
errors for this study is 2. That is to say that on average two associations detected as 
nominally significant at the 0.05 level would have occurred by chance alone.  Since 
there were a total of 6 such associations detected (counting the significant results 
for BMI, obesity, and waist circumference as only one), more than the expected 
chance finding, and because several of these associations with the rs5068 genotype 
reflected a consistent protective effect on cardiometabolic parameters, it is unlikely 
that chance alone explains the associations.  Thus, it is likely that at least some of 
these findings were not type I errors, particularly given the fact that the direction of 
the effects corresponded with prior expectations.   
 We also note that after fitting a regression model adjusted for age, gender 
and BMI, the associations between the G allele and values of HDL cholesterol, C-
reactive protein, metabolic syndrome and myocardial infarction were attenuated. 
These data could reveal how these metabolic associations might be mediated by the 
primary important correlation between the NPPA SNP and lower BMI. We further 
performed a regression analysis including NT-proANP in our model. The 
associations between the minor allele of rs5068 and BMI, prevalence of obesity and 
values of waist circumference still remained significant, while the associations 
between genotype and SBP and myocardial infarction remained marginally 
significant. These findings should be interpreted cautiously. Indeed, our data may 
indicate that rs5068 or genetic loci in linkage disequilibrium with it may affect 
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susceptibility for cardiometabolic diseases. There is also the possibility that rs5068 
alters lifelong levels of ANP, and this effect is not completely accounted for by the 
measurement of one value of NT-proANP in each individual. Moreover, it is 
important to remark that a lack of attenuation after assuming a regression model 
adjusted for NT-proANP does not exclude a possible biological role for ANP in 
determining the observed favorable metabolic phenotype. With respect to detect a 
relationship between plasma ANP levels and metabolic phenotype, we were 
probably limited by the size of our sample, our ability to directly measure ANP due 
to the short half life of ANP, and instability of the peptide under laboratory 
conditions. Although we tested for an association, we did not detect any difference 
between groups with respect to plasma ANP levels. 
Our model considered as a confounding variable, not ANP, but NT-proANP, 
which was significantly higher in the group characterized by the presence of the 
minor allele. Indeed, NT-proANP is secreted in equimolar amounts with ANP (27). 
Due to its longer half-life, greater laboratory stability and less variability in plasma 
concentration, NT-proANP is considered a reliable biomarker to estimate ANP 
secretion from the heart (27,28) but no evidences are present in literature regarding 
a biological action of NT-proANP. On the contrary, several findings support the 
view of ANP as an important metabolic regulator. Infusion of ANP at 
pharmacological doses into healthy lean men and head down bed rest position, both 
which increase plasma ANP levels, promote lipid mobilization and utilization 
(8,31). This lipolytic effect of ANP is independent of insulin or sympathetic 
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nervous system activation and is mediated by a cGMP-dependent pathway that 
induces the phosphorylation of hormone sensitive lipase and perilipin A via the 
activation of cGMP-dependent protein kinase I (32,33). Further, in a key 
Framingham study, NT-proANP and BNP correlated inversely with the metabolic 
syndrome and its individual components, even after adjustment for BMI (34). 
Based on these findings, we tested the hypothesis that rs5068 would have been 
associated with a favorable cardiometabolic phenotype in a representative sample 
of the adult general population.  
A replication study is clearly needed in order to confirm the validity of our 
data and the lack of replication in the current study is a limitation. An additional 
limitation is the low genotyping call rate. In order to support the validity of our 
findings from a statistical point of view we can assume that the failures occurred in 
a random fashion unrelated to any phenotype traits. Indeed, the genotype 
frequencies of rs5068 in our population are similar to the frequencies reported in 
the HapMap Project regarding a population from UTAH, in the Framingham Heart 
Study, Malmö Diet and Finrisk cohort. 
Our investigation, together with previous experimental data,  provide a 
rationale for the development of ANP or guanylyl cyclase-A agonist/ANP/BNP-
like drugs as potential cardiometabolic therapeutics that are able to target the 
complex metabolic syndrome on several different levels. Indeed, our recent report 
of the feasibility of orally delivered BNP in an animal model of experimental 
hypertension supports such a therapeutic direction (35,36). Further studies are 
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required to confirm our findings and to clarify the physiological mechanisms 
underlying the effects exerted by natriuretic peptides on metabolism. 
 In summary, our findings in a general community population demonstrate 
that the minor allele of rs5068 is associated with a favorable cardiometabolic 
profile characterized by higher levels of NT-proANP and HDL cholesterol, lower 
systolic blood pressure, prevalence of myocardial infarction, BMI, waist 
circumference, C-reactive protein levels and prevalence of metabolic syndrome. 
These findings, which both confirm previous findings regarding a link to blood 
pressure and extend the relationship of rs5068 to cardiometabolic homeostasis, 
suggest that rs5068 or genetic loci in linkage disequilibrium may affect 
susceptibility for cardiometabolic diseases. These findings further support the 
possible protective role of natriuretic peptides by their favorable effects on 
metabolic function, including body weight and lipid metabolism with clinical 
implications in disease prevention and innovative therapeutics.  
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 Characteristic  AA 
(n=1445) 
AG + GG 
(n=163) 
Unadjusted P-
value*   
Adjusted 
P-value 
†
 
Adjusted  
P-value 
‡
 
Adjusted  
P-value
 §
 
Females 746 (52%) 95 (58%) 0.108 0.122 0.173 0.396 
Age, yrs 61.5 (53.2, 70.4) 62.5 (54.6, 71.6) 0.182 0.208 0.300 0.998 
Age categories    0.183 0.211 0.295 0.935 
.     45-54 yrs 436 (30%) 41 (25%)     
.     55-64 yrs 433 (30%) 53 (33%)     
.     65-74 yrs 367 (25%) 39 (24%)     
.     75+ yrs 209 (14%) 30 (18%)     
Systolic blood pressure, mmHg 132 (116, 147) 129 (115, 144) 0.063 0.011 0.051 0.054 
Diastolic blood pressure, mmHg 73 (67, 80) 72 (66, 77) 0.063 0.132 0.247 0.262 
Creatinine, mg/dL 1.0  (0.9, 1.2) 1.0 (0.9, 1.1) 0.283 0.437 0.479 0.450 
NT-proBNP, pg/mL
║
 67.4 (27.8, 146.9) 80.2 (37.8, 175.1) 0.096 0.413 0.497 0.565 
NT- proANP, pg/mL 
║
 2188 (1374, 3238) 2584 (1693, 3842) < 0.001 0.002 0.006 - 
Ejection Fraction,% 65 (60, 68) 65 (60, 65) 0.701 0.916 0.897 0.642 
Ejection Fraction <40% 28 (2%) 1 (1%) 0.254 0.247 0.284 0.207 
Table 1.  Characteristics of the Study Population across the rs5068 Genotype 
 Characteristic  AA 
(n=1445) 
AG + GG 
(n=163) 
Unadjusted P-
value*   
Adjusted 
P-value 
†
 
Adjusted  
P-value 
‡
 
Adjusted  
P-value
 §
 
Ejection Fraction <50% 83 (6%) 6 (4%) 0.279 0.267 0.323 0.229 
Moderate to Severe Diastolic Dysfunction 106 (7%) 11 (7%) 0.627 0.458 0.432 0.173 
LV Dimension Index, cm/m
2
 2.6 (2.4, 2.8) 2.6 (2.4, 2.8) 0.236 0.321 0.910 0.689 
LV mass index, g/m
2
 94 (82, 109) 93 (82, 107) 0.297 0.315 0.565 0.337 
LA volume index, mL/m
2
 23.3 (19.5, 28.4) 23.9 (19.2, 27.9) 0.377 0.211 0.314 0.085 
 
Continuous data are summarized with medians and 25
th
 and 75
th
 percentile values, and categorical data with counts and percentages 
N-Terminal proANP, NT-proANP; N-Terminal proBNP, NT-proBNP, left ventricular, LV; left atrial, LA 
* P-value obtained from univariate regression model 
† 
P-value obtained from regression model adjusting for age and gender 
‡ 
P-value obtained from regression model adjusting for age, gender and BMI 
§ 
P-value obtained from regression model adjusting for age, gender, BMI and NT-proANP 
 
Table 1.  Characteristics of the Study Population across the rs5068 Genotype 
  
 
* Odds Ratio, 95% CI and P-value obtained from logistic regression univariate model 
† Odds Ratio, 95% CI and P-value obtained from logistic regression model adjusting for age and gender                        
‡ Odds Ratio, 95% CI and P-value obtained from logistic regression model adjusting for age, gender and BMI 
 
 
 
AA 
(n=1445) 
AG + GG 
(n=163) 
Odds Ratio (95% CI) 
[P-value] * 
Odds Ratio (95% CI) 
[P-value] † 
Odds Ratio (95% CI) 
[P-value] ‡ 
Verified Hypertension 425 (29%) 47 (29%) 0.97 (0.68, 1.39) [0.879] 0.91 (0.63, 1.31) [0.600] 1.01 (0.69, 1.48) [0.950] 
Coronary artery disease 185 (13%) 14 (9%) 0.64 (0.36, 1.13) [0.124] 0.57 (0.31, 1.05) [0.071] 0.61 (0.33, 1.12) [0.109] 
Myocardial Infarction 80 (6%) 3 (2%) 0.32 (0.10, 1.02) [0.055] 0.29 (0.09, 0.96) [0.042] 0.32 (0.10, 1.06) [0.061] 
Congestive Heart Failure 31 (2%) 5 (3%) 1.44 (0.55, 3.77) [0.453] 1.40 (0.52, 3.74) [0.504] 1.57 (0.58, 4.23) [0.373] 
Atrial Fibrillation 68 (5%) 10 (6%) 1.32 (0.67, 2.63) [0.421] 1.29 (0.63, 2.64) [0.487] 1.35 (0.66, 2.77) [0.417] 
Cerebrovascular Accident 20 (1%) 4 (2%) 1.79 (0.61, 5.31) [0.292] 1.76 (0.59, 5.26) [0.311] 1.79 (0.60, 5.37) [0.300] 
Diabetes Mellitus type 2 108 (7%) 13 (8%) 1.07 (0.59, 1.95) [0.818] 1.05 (0.57, 1.93) [0.875] 1.26 (0.68, 2.35) [0.459] 
Table 2. Prevalence of Cardiovascular Diseases and Diabetes Mellitus type 2 across the rs5068 Genotype.  
  
 
Characteristic 
AA 
(n=1445) 
AG + GG 
(n=163) 
Unadjusted 
P-value* 
Adjusted 
P-value
†
  
Adjusted  
P-value 
‡
 
Adjusted  
P-value 
§
 
Body Mass Index, kg/m
2
 27.9 (25, 31.6) 26.7 (24.3, 29.4) 0.003 0.006 - 0.006
║
 
Obesity (BMI ≥  30 kg/m2 ) 503 (35%) 36 (22%) 0.001 0.002 - 0.001║ 
Waist Circumference, cm 93 (82, 101) 90 (80, 96) 0.006 0.021 - 0.025
║
 
Total Cholestorol, mg/dL   200 (178, 222) 207 (183, 231) 0.190 0.274 0.301 0.336 
HDL Cholestorol, mg/dL 42 (35, 54) 47 (39, 58) 0.004 0.019 0.115 0.205 
LDL Cholestorol, mg/dL 125 (105, 146) 133 (108, 154) 0.296 0.275 0.280 0.197 
Triglycerides, mg/dL
¶
 129 (95, 182) 123 (88, 169) 0.102 0.096 0.295 0.234 
Serum Glucose, mg/dL
¶
 94 (89, 101) 93.0 (89, 101) 0.573 0.535 0.960 0.486 
Insulin, µU/mL
 ¶ #
 5.2 (3.6, 7.8) 4.7 (3.5, 7.2) 0.059 0.069 0.446 0.469 
C-Reactive Protein, mg/dL
¶
 0.20 (0.09, 0.44) 0.17 (0.07, 0.40) 0.083  0.027 0.220 0.120 
Metabolic Syndrome 296 (20%) 21 (13%) 0.024 0.025 0.286 0.133 
            Continuous data are summarized with medians and 25th and 75th percentile values, and categorical data with counts and percentages. High density lipoprotein, HDL; 
               low density lipoprotein, LDL. 
* 
P-value obtained from univariate regression model;
† 
P-value obtained from regression model adjusting for age and gender; 
‡ 
P-value 
               obtained from regression model adjusting for age, gender and BMI; 
§ 
P-value obtained from regression model adjusting for age, gender, BMI and NT-proANP;    
                       ║ 
BMI not adjusted for in the model; adjusting factors were age, gender, and NT-proANP only; 
¶
 P-values based on logarithmic transformed variable; 
# 
Analyzed on 
                subgroup of subjects free of diabetes mellitus type 1 and 2 
Table 3. Metabolic Parameters in the Study Population according to the rs5068 Genotype  
  
Figure 1A: Prevalence of Obesity in the Study Population according to Genotype 
Obesity was defined as BMI 30 kg/m2.  
*P value obtained from logistic regression model adjusting for age and gender. 
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Figure 1B: Prevalence of Metabolic Syndrome in the Study Population according to 
Genotype  
*P value obtained from logistic regression model adjusting for age and gender.  
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